Skip to main content
    C

    Cellectis SA (CLLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.04
    -0.14 (-11.86%)

    Market Cap: $118.86M

    Last updated: Nov 17, 2026 at 10:55 AM ET

    Cellectis SA (CLLS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Cellectis SA (CLLS) to earn -$0.78 per share in the fiscal year ending Dec 31, 2026, on revenue of $49.65M. Of 5 analysts, 2 rate the stock Buy or Strong Buy, 2 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 40% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy240.0%
    Hold240.0%
    Sell00.0%
    Strong Sell120.0%
    Consensus
    Hold
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 8.9%.

    Fiscal year ending Dec 31, 2026
    -$0.78
    EPS consensus, revenue $49.65M
    Fiscal year ending Dec 31, 2027
    -$0.71
    EPS consensus, revenue $45.24M
    Fiscal year ending Dec 31, 2028
    -$1.32
    EPS consensus, revenue $79.64M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.78-$1.16 to -$0.505$49.65M$29.89M to $66.29M4
    Dec 31, 2027-$0.71-$1.25 to -$0.414$45.24M$21.63M to $64.50M4
    Dec 31, 2028-$1.32-$2.55 to -$0.362$79.64M$35.16M to $136.40M1

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.18-$0.26 to -$0.127$13.69M$9.80M to $18.23M7

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202632

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.89.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.78-$0.79-$0.82-$0.89-$0.89N/A
    Fiscal year ending Dec 31, 2027-$0.71-$0.84-$0.82-$0.89-$0.89N/A

    Frequently Asked Questions About CLLS

    What is the CLLS stock forecast?

    Consensus analyst estimates put Cellectis SA's EPS at -$0.78 for the fiscal year ending Dec 31, 2026, on revenue of $49.65M. The consensus rating from 5 analysts is Hold.

    How do analysts rate CLLS stock?

    Of 5 analysts covering Cellectis SA, 0 rate it Strong Buy, 2 Buy, 2 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from CLLS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.78, with estimates from -$1.16 to -$0.50 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.71, with estimates from -$1.25 to -$0.41 from 4 analysts.

    What revenue do analysts expect from Cellectis SA next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $49.65M, with estimates from $29.89M to $66.29M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $45.24M, with estimates from $21.63M to $64.50M.

    How many analysts cover CLLS?

    5 analysts rate Cellectis SA stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.